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Iron is a vital element for all living organisms because
it is essential for many metabolic processes, such as
oxygen transport, DNA synthesis, and electron transport
[1]. However, redox active free iron can catalyze
generation of highly reactive oxygen species, such as
hydroxyl, alkoxyl, and peroxyl radicals via Fenton
chemistry and Haber-Weiss reactions [2].
As an iron overload can increase the concentration of
catalytically active free iron, it has been considered to be
a possible risk factor of various chronic diseases
including cancer and cardiovascular disease in which
oxidative stress is closely involved in pathogenesis [3].
Despite the biological plausibility of the results of
experimental studies, however, epidemiologic studies
on associations between markers of body iron stores
like serum ferritin or transferrin saturation (%TS) and
mortality have yielded conflicting results [4-7]. For
example, in the US general population using data
from the third National Health and Nutrition
Examination Survey (NHANES III), neither serum
ferritin nor %TS was associated with all-cause
mortality [7]. However, %TS was inversely
associated with overall mortality and with mortality
from cardiovascular causes in a study using earlier
data from NHANES I [6], while another study using
the same NHANES I data reported that subjects with
a %TS 55% had an increased risk of all-cause
mortality [5]. Other cohort studies have shown
inconsistent results as well [8,9].
Interestingly, even though both serum ferritin and
%TS have been commonly used as markers of body iron
stores in epidemiological studies, our previous study
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Objectives: Even though experimental studies have suggested that iron can be involved in generating oxidative stress,
epidemiologic studies on the association of markers of body iron stores with cardiovascular disease or cancer remain
controversial. This study was performed to examine the association of serum ferritin and transferrin saturation (%TS) with
all-cause, cancer, and cardiovascular mortality.
Methods: The study subjects were men aged 50 years or older and postmenopausal women of the Third National Health
and Nutrition Examination Survey 1988-1994. Participants were followed-up for mortality through December 31, 2006.
Results: Serum ferritin was not associated with all-cause, cancer, or cardiovascular mortality for either men or
postmenopausal women. However, all-cause, cancer, and cardiovascular mortality were inversely associated with %TS in
men. Compared with men in the lowest quintile, adjusted hazard ratios for all-cause, cancer, and cardiovascular mortality
were 0.85, 0.86, 0.76, and 0.74 (p for trend <0.01), 0.82, 0.73, 0.75, and 0.63 (p for trend <0.01), and 0.86, 0.81, 0.72,
and 0.76 (p for trend <0.01), respectively. For postmenopausal women, inverse associations were also observed for all-
cause and cardiovascular mortality, but cancer mortality showed the significantly lower mortality only in the 2nd quintile of
%TS compared with that of the 1st quintile.
Conclusions: Unlike speculation on the role of iron from experimental studies, %TS was inversely associated with all-
cause, cancer and cardiovascular mortality in men and postmenopausal women. On the other hand, serum ferritin was not
associated with all-cause, cancer, or cardiovascular mortality.
Key words: Iron, Ferritins, Transferrin % saturation, Mortality, Neoplasms, Cardiovascular diseases
J Prev Med Public Health 2012;45(3):196-203
0 0S SJ JH HJ JO OB BM M" "S SU UJ JD DM MF F
Corresponding author : Duk-Hee Lee, MD, PhD
680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, Korea
Tel: +82-53-420-6960, Fax: +82-53-425-2447, E-mail: lee_dh@knu.ac.kr
Received: 11 November 2011, Accepted: 25 January 2012
This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
cc .BSLFSTPG#PEZ*SPO4UPSFTBOE.PSUBMJUZ
+1SFW.FE1VCMJD)FBMUI	

using data from NHANES III observed that serum
ferritin and %TS were differently associated with several
markers of oxidative stress or inflammation [10]. For
example, serum ferritin was inversely associated with
several serum antioxidant vitamin levels and positively
associated with C-reactive protein as an inflammatory
marker, and %TS showed opposite results.
Therefore, even though a previous study reported no
association of serum ferritin and %TS with mortality
using data from NHANES III [7], considering the
opposite associations of serum ferritin and %TS with
markers of oxidative stress or inflammation in the same
dataset [10], the association of serum ferritin and %TS
with mortality needs to be carefully reevaluated. In
particular, the previous study’s design focusing on all-
cause mortality among persons aged 20 years or older
[7] may not be appropriate to investigate associations
with mortality due to oxidative-stress related diseases
because these kinds of diseases may mainly develop
among the elderly or postmenopausal women.
Therefore, we evaluated the associations of serum
ferritin and %TS with all-cause, cancer, and
cardiovascular mortality among subjects aged 50 years
or older of the NHANES III dataset.
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I. Study Population
The NHANES III, conducted by the National Center for
Health Statistics of the Centers for Disease Control and
Prevention from 1988 through 1994, was a complex,
multi-stage probability survey designed to provide national
estimates of the health and nutritional status of the US
civilian, noninstitutionalized population aged two months
and older [11]. Of the 8654 NHANES III participants aged
50 years or older, 2959 were excluded for the following
reasons: first, 1573 had missing serum ferritin or missing
%TS; second, 1141 had missing covariate values; third, 2
had missing mortality follow-up data; finally, because
serum ferritin and %TS status are substantially different by
menopausal status, we also excluded 243 premenopausal
women. The remaining 5695 NHANES III participants not
having these exclusion criteria were available for the
current analysis.
The NHANES institutional review board (IRB)
approved the protocol for NHANES III and documented
consent was obtained from all participants. A detailed
description of the NHANES III IRB approval is
available elsewhere [12].
II. Measurement
Data collection, quality control procedures, and
laboratory methods are described in detail elsewhere
[11]. Briefly, demographic characteristics and health-
related information were collected using a standardized
questionnaire during the in-home interview. In order to
obtain physical examination data, participants visited a
mobile examination center.
Serum ferritin was measured by a single-incubation
two-site immunoradiometric assay (BioRad Laboratories,
Hercules, CA, USA). Serum iron and total iron-binding
capacity were measured by a modified automated AAII-
25 colorimetric method using an RFA or RFA-300
automated ferrozine colorimetric analyzer system
(Alpkem Inc., Clackams, OR, USA). %TS was calculated
by dividing the serum iron concentration by the serum
total iron-binding capacity and multiplying by 100.
III. Mortality Follow-up
NHANES III survey participants were followed for
mortality through December 31, 2006. Mortality
ascertainment is based upon the results from a
probabilistic match between NHANES III and National
Death Index death certificate records. Matching was
based on 12 identifiers (e.g., social security number, first
name, sex, and date of birth). A detailed description of
the mortality linkage methodology is available
elsewhere [13].
Cause of death coding for all US deaths occurring
prior to 1999 follows the 9th revision of the International
Statistical Classification of Disease, Injuries, and Causes
of Death (ICD-9) guidelines, while that for all deaths
after 1998 follows the ICD-10 guidelines. Therefore, the
Underlying Cause of Death 113 Groups All Years
(UCOD 113) variable was created as a recode of all
deaths occurring prior to 1999 coded under ICD-9
guidelines into comparable ICD-10 based underlying
cause of death groups. We used UCOD113 for the
current analyses. UCOD 019 to 044 (ICD-10 code: C00-
C97 and D00-D48) was defined as death because of
cancer, and UCOD 054 to 075 (ICD-10 code: I00-I78
and I80-I99) was defined as death because of
cardiovascular disease. A detailed description of
UCOD113 is available elsewhere [14,15].
IV. Statistical Analysis
As serum ferritin and %TS status differ by gender,
stratified analyses by gender were performed. Study ,J4V,JNFUBM
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Table 1. Demographic and health behavior variables of study participants according to quintiles of serum ferritin
p-trend
1 Q1
∔68.0
Q2
69.0-118.0
Q3
119.0-181.0
Q4
182.0-288.0
Q5
∕289.0
Men
Quintiles of serum ferritin (ng/mL)
Meanstandard deviation
Age (y)
Poverty income ratio
Years of education
Alcohol intake (g/d)
Body mass index
Proportion (%)
Non-Hispanic white
Current smoker
Physically inactive
68.9 10.2
02.5 1.80
9.5 4.7
07.5 17.4
26.4 4.20
57.6
17.8
21.0
67.6 10.4
2.8 2.0
9.9 4.5
08.3 18.0
26.6 4.40
61.0
22.5
21.0
67.0 10.3
2.9 2.0
10.1 4.50
10.1 20.7
27.0 4.40
59.6
23.7
17.1
66.1 10.0
2.8 2.0
9.9 4.5
10.7 24.9
27.4 4.70
50.9
25.4
20.5
66.1 10.0
2.8 2.0
10.3 4.40
16.1 44.3
27.3 4.80
54.2
20.7
19.2
< 0.01 
0.01 
< 0.01 
< 0.01 
< 0.01 
0.84
0.71
0.87
1p-trend was tested by a generalized linear model for continuous variables and the Mantel-Haenszel chi-squared test for categorical variables.
p-trend Q1
∔46.0
Q2
47.0-80.0
Q3
81.0-123.0
Q4
124.0-193.0
Q5
∕194.0
Postmenopausal women
Quintiles of serum ferritin (ng/mL)
Meanstandard deviation
Age (y)
Poverty income ratio
Years of education
Alcohol intake (g/d)
Body mass index
Proportion (%)
Non-Hispanic white
Current smoker
Physically inactive
68.5 10.6
2.5 1.8
10.0 4.20
3.2 9.3
26.6 5.70
63.2
15.9
34.2
67.8 10.5
2.5 1.9
10.0 4.10
3.3 9.8
27.5 5.90
62.1
14.2
32.0
66.9 10.2
2.4 1.8
10.3 4.00
3.0 8.6
28.0 6.10
56.7
14.9
28.6
67.8 9.7
02.2 1.6
09.9 4.1
03.5 9.3
28.3 5.9
52.5
17.5
30.9
67.6 10.4
2.3 1.8
10.0 4.00
04.0 12.8
28.7 6.30
51.7
15.1
35.4
0.17 
< 0.01 
0.67 
0.23 
< 0.01 
0.17
0.77
0.85
Table 2. Demographic and health behavior variables of study participants according to quintiles of transferrin saturation
p-trend
1 Q1
∔18.0
Q2
18.1-23.1
Q3
23.2-28.2
Q4
28.3-35.1
Q5
∕35.2
Men
Quintiles of transferrin saturation (%)
Meanstandard deviation
Age (y)
Poverty income ratio
Years of education
Alcohol intake (g/d)
Body mass index
Proportion (%)
Non-Hispanic white
Current smoker
Physically inactive
67.6 10.5
2.4 1.7
9.4 4.3
07.9 15.7
27.0 4.80
52.4
26.4
24.0
67.5 10.0
2.7 2.0
9.5 4.8
08.6 21.5
27.2 4.60
51.9
21.9
20.0
66.6 10.3
2.9 1.9
10.5 4.30
09.6 19.4
27.1 4.30
59.7
20.0
17.7
67.2 10.2
2.9 2.0
10.2 4.70
11.4 27.8
26.8 4.50
58.6
18.0
20.2
66.9 10.3
2.8 2.0
10.2 4.50
15.2 42.3
26.6 4.30
60.8
23.7
16.8
0.25 
< 0.01 
< 0.01 
< 0.01 
0.08 
0.19
< 0.01
0.12
1 p-trend was tested by a generalized linear model for continuous variables and the Mantel-Haenszel chi-squared test for categorical variables.
p-trend Q1
∔46.0
Q2
47.0-80.0
Q3
81.0-123.0
Q4
124.0-193.0
Q5
∕194.0
Postmenopausal women
Quintiles of transferrin saturation (%)
Meanstandard deviation
Age (y)
Poverty income ratio
Years of education
Alcohol intake (g/d)
Body mass index
Proportion (%)
Non-Hispanic white
Current smoker
Physically inactive
67.8 10.5
2.2 1.7
9.6 4.3
2.7 7.5
28.6 6.80
52.8
16.9
37.5
67.7 10.3
2.3 1.6
10.0 4.00
3.0 9.9
28.3 5.80
55.0
14.5
32.3
68.0 10.2
2.4 1.9
10.3 4.00
3.0 9.5
27.9 6.10
59.2
14.9
32.3
67.2 10.1
2.4 1.8
10.1 4.10
04.1 12.6
27.8 5.90
55.4
13.7
30.5
67.9 10.4
2.6 1.8
10.1 4.20
04.3 10.2
26.4 5.10
63.9
17.5
28.4
0.83 
< 0.01 
0.06 
< 0.01 
< 0.01 
0.03
0.66
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subjects were categorized using gender specific quintiles
of serum ferritin and %TS. Hazard ratios were estimated
by Cox proportional hazard models. Adjusting variables
were demographic characteristics, such as age in years
(continuous), race-ethnicity (non-Hispanic white, non-
Hispanic black, Mexican-American, and others), poverty
income ratio (family income divided poverty threshold
value, continuous), and years of education (continuous),
and health related variables, such as smoking (never,
former, and current), alcohol consumption (g/d,
continuous), body mass index (BMI, kg/m
2, continuous)
and physical activity (none, moderate, and vigorous). We
additionally adjusted for the Charlson comorbidity index
(CCI, continuous). The CCI, which was developed by
Charlson et al. [16], to classify comorbid conditions that
might alter the risk of mortality, was found to be a valid
method of estimating risk of death from comorbid
disease in longitudinal studies [17,18]. Therefore, we
used the CCI for adjusting for comorbidity. CCI
calculation used the following data: self-reported
personal disease history data by questionnaire
(information on myocardial infarction, congestive heart
failure, stroke, asthma, bronchitis, emphysema, arthritis,
lupus, gout, stomach ulcer, liver disorder, cancer,
cataract, thyroid disease, osteoporosis, dyslipidemia,
gallbladder stone, kidney stone, diabetes, and
hypertension); measured blood pressure and use of
hypertension medication for defining hypertension; and
measured plasma glucose and use of diabetic medication
for defining diabetes.
All statistical analyses were performed with SAS
version 9.2 (SAS Inc., Cary, NC, USA) and SUDAAN
version 9.0 (RTI International, Research Triangle Park,
NC, USA). Estimates of the main results were calculated
accounting for stratification and clustering [19],
adjusting for age, race-ethnicity, and poverty income
ratio instead of using sample weights; this adjustment
has been regarded as a good compromise between
efficiency and bias [19,20]. As results were very similar
with SAS and SUDAAN, we present the results based
on SAS.
3&46-54
Demographic characteristics and health related
information according to quintile of serum ferritin and
%TS are shown in Tables 1 and 2, respectively. Subjects
with high serum ferritin tended to have a higher BMI. In
men, subjects with high serum ferritin consumed more
alcohol, but there were no significant tendencies
specific to the postmenopausal women. Subjects with
high %TS showed tendencies opposite to those with
high serum ferritin for BMI. Subjects with high %TS
also consumed more alcohol, similarly to the results of
ferritin. The correlation coefficients between serum
ferritin and %TS were +0.21 for both men and
postmenopausal women.
The hazard ratios for all-cause, cancer, and cardiovascular
mortality are shown in Tables 3, 4, and 5, respectively.
Serum ferritin was not associated with any mortality in
either men or postmenopausal women. On the other hand,
%TS showed strong inverse associations with all-cause,
cancer, and cardiovascular mortality in men. Compared
with men in the lowest quintile, adjusted hazard ratios for
all-cause mortality were 0.85, 0.76, 0.76, and 0.74 (p for
trend < 0.01), adjusted hazard ratios for cancer mortality
were 0.82, 0.73, 0.75, and 0.63 (p for trend < 0.01), and
adjusted hazard ratios for cardiovascular mortality were 0.86,
0.81, 0.72, and 0.76 (p for trend < 0.01). In postmenopausal
women, %TS was also inversely associated with all-
cause and cardiovascular mortality. Adjusted hazard
ratios for all-cause and cardiovascular mortality across
quintiles of %TS, compared with postmenopausal
women in the lowest quintile, were 0.84, 0.85, 0.84, and
0.83 (p for trend <0.05), and 0.97, 0.87, 0.76, and 0.73
(p for trend <0.01), respectively. For cancer mortality in
postmenopausal women, although a decreasing trend
was not observed, the hazard ratio of the second quintile
was 0.48 (95% confidence interval [CI], 0.30 to 0.76)
compared with the ratio in the lowest quintile. 
%*4$644*0/
In the current study, serum ferritin was not associated
with all-cause, cancer, or cardiovascular mortality. As
serum ferritin was positively associated with several
markers of oxidative stress or inflammation in our
previous study [10], we had hypothesized the positive
associations between serum ferritin and mortality.
However, the results did not support this hypothesis. On
the other hand, consistent with the inverse associations
between %TS and markers of oxidative stress or
inflammation [10], %TS was inversely associated with
all-cause and cardiovascular mortality in both men and
postmenopausal women. Men also showed the inverse
association between %TS and cancer mortality.
It is worthwhile to compare our results to those of
Menke et al. [7] in more detail because both studies used
the dataset from NHANES III. The lack of an
association with serum ferritin was also observed by ,J4V,JNFUBM
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Table 3. Hazard ratios (95% confidence intervals) of all-cause mortality across quintiles of serum ferritin and
transferrin saturation
p-trend
1 Q1
∔68.0
Q2
69.0 -118.0
Q3
119.0 -181.0
Q4
182.0 -288.0
Q5
∕289.0
Men
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
2
Model 2
3
359 / 580
1.00 (reference)
1.00 (reference)
321 / 582
0.88 (0.75, 1.02)
0.93 (0.80, 1.08)
320 / 574
0.98 (0.84, 1.14)
1.01 (0.87, 1.18)
294 / 576
0.89 (0.76, 1.04)
0.94 (0.81, 1.10)
304 / 579
0.97 (0.83, 1.13)
1.03 (0.88, 1.20)
0.750
0.771
1 p-trend was studied in a model with only a linear term for ferritin or transferrin saturation.
2 Adjusted for age, race-ethnicity, poverty income ratio, years of education, cigarette smoking, alcohol consumption, body mass index, and physical activity.
3 Adjusted for the same variables as in model 1 plus the Charlson comorbidity index.
p-trend Q1
∔46.0
Q2
47.0-80.0
Q3
81.0-123.0
Q4
124.0-193.0
Q5
∕194.0
Postmenopausal women
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
Model 2
276 / 565
1.00 (reference)
1.00 (reference)
259 / 557
1.01 (0.85, 1.20)
1.01 (0.85, 1.20)
236 / 559
0.97 (0.82, 1.16)
1.00 (0.84, 1.19)
246 / 560
0.91 (0.77, 1.08)
0.92 (0.77, 1.09)
277 / 563
1.15 (0.97, 1.36)
1.14 (0.97, 1.35)
0.37
0.39
p-trend Q1
∔18.0
Q2
18.1-23.1
Q3
23.2-28.2
Q4
28.3-35.1
Q5
∕35.2
Men
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
360 / 575
1.00 (reference)
1.00 (reference)
333 / 584
0.89 (0.77, 1.03)
0.85 (0.74, 0.99)
304 / 576
0.78 (0.67, 0.91)
0.76 (0.65, 0.88)
304 / 579
0.77 (0.66, 0.90)
0.76 (0.65, 0.89)
297 / 577
0.73 (0.63, 0.85)
0.74 (0.63, 0.86)
< 0.01
< 0.01
p-trend Q1
∔15.5
Q2
15.6-19.9
Q3
20.0-24.1
Q4
24.2-30.1
Q5
∕30.2
Postmenopausal women
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
288 / 557
1.00 (reference)
1.00 (reference)
250 / 564
0.83 (0.70, 0.98)
0.84 (0.71, 1.00)
257 / 563
0.83 (0.70, 0.99)
0.85 (0.72, 1.01)
239 / 561
0.82 (0.69, 0.98)
0.84 (0.70, 0.99)
260 / 559
0.82 (0.69, 0.97)
0.83 (0.70, 0.98)
0.03
< 0.05
Table 4. Hazard ratios (95% confidence intervals) of cancer mortality across quintiles of serum ferritin and
transferrin saturation
p-trend
1 Q1
∔68.0
Q2
69.0-118.0
Q3
119.0-181.0
Q4
182.0-288.0
Q5
∕289.0
Men
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
2
Model 2
3
88 / 580
1.00 (reference)
1.00 (reference)
77 / 582
0.85 (0.62, 1.15)
0.87 (0.64, 1.19)
77 / 574
0.92 (0.67, 1.25)
0.93 (0.69, 1.27)
77 / 576
0.91 (0.67, 1.24)
0.94 (0.69, 1.28)
78 / 579
0.98 (0.72, 1.34)
1.01 (0.74, 1.38)
0.95
0.79
1 p-trend was studied in a model with only a linear term for ferritin or transferrin saturation.
2 Adjusted for age, race-ethnicity, poverty income ratio, years of education, cigarette smoking, alcohol consumption, body mass index, and physical activity.
3 Adjusted for the same variables as in model 1 plus the Charlson comorbidity index.
p-trend Q1
∔46.0
Q2
47.0-80.0
Q3
81.0-123.0
Q4
124.0-193.0
Q5
∕194.0
Postmenopausal women
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
Model 2
47 / 565
1.00 (reference)
1.00 (reference)
46 / 557
1.01 (0.67, 1.52)
1.01 (0.68, 1.53)
43 / 559
0.98 (0.65, 1.48)
0.99 (0.65, 1.50)
54 / 560
1.12 (0.75, 1.66)
1.13 (0.76, 1.67)
45 / 563
1.02 (0.68, 1.55)
1.02 (0.67, 1.54)
0.74
0.76
p-trend Q1
∔18.0
Q2
18.1-23.1
Q3
23.2-28.2
Q4
28.3-35.1
Q5
∕35.2
Men
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
94 / 575
1.00 (reference)
1.00 (reference)
83 / 584
0.84 (0.63, 1.13)
0.82 (0.61, 1.11)
76 / 576
0.74 (0.54, 1.00)
0.73 (0.54, 0.99)
78 / 579
0.75 (0.56, 1.02)
0.75 (0.56, 1.02)
66 / 577
0.63 (0.46, 0.86)
0.63 (0.46, 0.87)
< 0.01
< 0.01
p-trend Q1
∔15.5
Q2
15.6-19.9
Q3
20.0-24.1
Q4
24.2-30.1
Q5
∕30.2
Postmenopausal women
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
52 / 557
1.00 (reference)
1.00 (reference)
27 / 564
0.47 (0.30, 0.75)
0.48 (0.30, 0.76)
55 / 563
0.96 (0.66, 1.41)
0.97 (0.66, 1.42)
45 / 561
0.79 (0.53, 1.18)
0.80 (0.54, 1.20)
56 / 559
0.95 (0.65, 1.40)
0.96 (0.66, 1.41)
0.49
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Menke et al., while the inverse association between %TS
and mortality found in our study differed from the lack
of association that they found. In spite of using the same
dataset, the results differed primarily due to different
inclusion criteria of study subjects. We analyzed only the
subjects aged 50 years or older while Menke et al.
analyzed the subjects aged 20 years or older. The
possible harmful effect of iron that has been suspected to
be caused by oxidative stress and the accumulation of
oxidant-damage, which can cause chronic diseases such
as cancer and cardiovascular disease or death, may
require a long time. Therefore, we hypothesized that it
would be more appropriate to study older persons to
explore the associations between markers of iron and
mortality because cancer or cardiovascular mortality are
lower in young people [21,22]. In fact, the Menke et al.
study [7] separately reported the results of postmenopausal
women and found results similar to ours, but they
interpreted the findings as being due to chance or
remaining confounders. Unlike our hypothesis, however,
mortality was found not to be positively associated with
any marker of iron, even among subjects aged 50 years
or older, but only %TS was inversely associated with
mortality. In fact, the previous study reporting an inverse
association between %TS and all-cause mortality using
the NHANES I also had subjects aged 45 years or older
[6]. At present, it is unclear why %TS inversely
predicted mortality. One speculation is that moderately
increased %TS may act as an antioxidant reaction
through binding free iron because the generation of free
radicals is caused only by catalytically active free iron.
However, one study using the data from NHANES I
reported that subjects with a %TS 55% had an
increased risk of all-cause mortality [5]. These
conflicting results may be related to levels of %TS. %TS
has been criticized as a poor measure of iron stores
because it reflects iron stores only when it is fully
depleted (%TS <16%) or fully overloaded (%TS >60%)
[23,24]. From this viewpoint, only a very high %TS
level can represent an iron overload and possibly
increased free iron. In the current study, the cutoff points
for %TS of the highest quintile in men and
postmenopausal women were %TS 35.2% and %TS
30.2%, respectively. When we repeated the analyses
to compare subjects with %TS 55% vs. < 55%, an
increased risk of all-cause mortality was observed
among men with an adjusted hazard ratio of 1.49 (95%
CI, 1.07 to 2.08). However, risk of cancer and
cardiovascular mortality in men and risk of any mortality
in postmenopausal women was not increased even
Table 5. Hazard ratios (95% confidence intervals) of cardiovascular mortality across quintiles of serum ferritin and
transferrin saturation
p-trend
1 Q1
∔68.0
Q2
69.0-118.0
Q3
119.0-181.0
Q4
182.0-288.0
Q5
∕289.0
Men
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
2
Model 2
3
158 / 580
1.00 (reference)
1.00 (reference)
160 / 582
0.99 (0.79, 1.23)
1.07 (0.86, 1.34)
149 / 574
1.06 (0.84, 1.32)
1.09 (0.87, 1.37)
132 / 576
0.91 (0.72, 1.14)
0.98 (0.78, 1.24)
141 / 579
1.02 (0.81, 1.29)
1.11 (0.88, 1.40)
0.89
0.63
1 p-trend was studied in a model with only a linear term for ferritin or transferrin saturation
2 Adjusted for age, race-ethnicity, poverty income ratio, years of education, cigarette smoking, alcohol consumption, body mass index, and physical activity.
3 Adjusted for the same variables as in model 1 plus the Charlson comorbidity index.
p-trend Q1
∔46.0
Q2
47.0-80.0
Q3
81.0-123.0
Q4
124.0-193.0
Q5
∕194.0
Postmenopausal women
Quintiles of serum ferritin (ng/mL)
Death/no. of subjects
Model 1
Model 2
133 / 565
1.00 (reference)
1.00 (reference)
123 / 557
1.00 (0.78, 1.27)
1.00 (0.78, 1.27)
110 / 559
0.95 (0.73, 1.22)
0.99 (0.77, 1.28)
122 / 560
0.95 (0.74, 1.22)
0.96 (0.75, 1.23)
133 / 563
1.15 (0.91, 1.47)
1.15 (0.90, 1.47)
0.40
0.39
p-trend Q1
∔18.0
Q2
18.1-23.1
Q3
23.2-28.2
Q4
28.3-35.1
Q5
∕35.2
Men
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
165 / 575
1.00 (reference)
1.00 (reference)
155 / 584
0.91 (0.73, 1.13)
0.86 (0.69, 1.07)
150 / 576
0.84 (0.68, 1.06)
0.81 (0.65, 1.02)
132 / 579
0.73 (0.58, 0.92)
0.72 (0.57, 0.91)
138 / 577
0.75 (0.60, 0.94)
0.76 (0.60, 0.95)
<0.01
<0.01
p-trend Q1
∔15.5
Q2
15.6-19.9
Q3
20.0-24.1
Q4
24.2-30.1
Q5
∕30.2
Postmenopausal women
Quintiles of transferrin saturation (%)
Death/no. of subjects
Model 1
Model 2
144 / 557
1.00 (reference)
1.00 (reference)
137 / 564
0.94 (0.74, 1.19)
0.97 (0.77, 1.23)
127 / 563
0.84 (0.66, 1.07)
0.87 (0.68, 1.11)
104 / 561
0.75 (0.58, 0.96)
0.76 (0.59, 0.98)
109 / 559
0.71 (0.55, 0.92)
0.73 (0.57, 0.94)
<0.01
<0.01 ,J4V,JNFUBM
+1SFW.FE1VCMJD)FBMUI	

among subjects with %TS 55% (data not shown). As
there were only small numbers of subjects with %TS 
55% in this study (51 subjects in men, and 19 subjects in
postmenopausal women), the association between very
high %TS and mortality needs to be evaluated in future
studies with a sufficient number of study subjects with
%TS 55%.
Even though serum ferritin is used as the most reliable
marker of stored iron [25], epidemiological findings on
serum ferritin in relation to the risk of cancer or
cardiovascular disease are inconsistent. Some studies
have reported that elevated serum ferritin was associated
with a high risk of cancer or cardiovascular disease [26-
28] while other studies reported that there is no
association between serum ferritin and cancer or
cardiovascular disease [29,30]. Indeed, serum ferritin
seems to be complicatedly connected with catalytically
active free iron. Like transferrin, ferritin can act as an
anti-oxidant by sequestering unbound or free iron
[31,32]. However, there are studies showing that free
iron may be more easily released and presumably more
available for participation in redox reactions as ferritin
iron content increases [31,33].
Our study has several limitations. First of all, even
though we used serum ferritin and %TS as markers of
body iron stores, iron-induced oxidative stress requires
catalytically active free iron. Therefore, neither of these
markers may be appropriate to reflect the levels of
catalytically active free iron. As it would be practically
very difficult to measure catalytically active free iron in
human serum, the failure to find possible positive
associations of serum ferritin or %TS should not be
regarded as evidence of the lack of harmfulness of iron.
Another limitation was that serum ferritin and
transferrin saturation may be affected by within-
individual variability even though NHANES III was
conducted with a well-designed protocol and quality
control to minimize flaws such as within-individual
variability.
In conclusion, we found that ferritin was not
associated with the risk of all-cause, cancer, or
cardiovascular mortality in men or postmenopausal
women aged 50 years or older while %TS was inversely
associated with all-cause, cancer, and cardiovascular
mortality. These results appear to show that a moderately
high %TS may be protective against oxidative stress.
These findings may be helpful in understanding the
association between body iron and chronic disease
which is related to oxidative stress.
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